Perfluorohexyloctane: Side Effects, Uses & Monitoring
MIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
- Data source
- FDA labeling via NIH DailyMed (label 6b283c02…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
MIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
Conditions associated with Perfluorohexyloctane in labeling
Frequently Asked Questions
What is Perfluorohexyloctane used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Perfluorohexyloctane?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does Perfluorohexyloctane require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Perfluorohexyloctane.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.